A multicenter and post-marketing surveillance study to evaluate the safety and effectiveness of a sodium alginate-based raft-forming antacid oral suspension in Indian patients with heartburn and indigestion
DOI:
https://doi.org/10.18203/2320-6012.ijrms20260962Keywords:
Alginate-based antacid, Dyspepsia, Gastric acid, Gastric regurgitation, HeartburnAbstract
Background: This study evaluated the safety and effectiveness of a sodium alginate-based raft-forming antacid oral suspension in Indian patients with heartburn and indigestion.
Methods: This multicenter post-marketing surveillance study, conducted across five centers in India, included adult patients with heartburn and indigestion prescribed a sodium alginate-based antacid suspension (10-20 ml after meals and at bedtime) for 7 days. Patients were evaluated on day 8 (±2). Effectiveness was assessed by adequate symptom relief, improvement in RDQ frequency and severity scores, reduction in symptom duration, and improvement in night-time symptoms. Safety was evaluated based on reported adverse drug reactions and global tolerability assessments by patients and investigators.
Results: Of 319 enrolled patients, 297 completed the study. After 7 days, adequate relief was reported by 95.6% for heartburn and 96.6% for indigestion. RDQ frequency and severity scores significantly improved (both ~74-76% reduction; p<0.0001), with marked reductions in daily symptom duration and nighttime episodes. Only one non-serious, unrelated ADR was reported, and tolerability was rated “good” by ~90% of patients and investigators.
Conclusions: The sodium alginate-based raft-forming antacid oral suspension provided effective relief of heartburn and indigestion, reflected by greater than 95% adequate relief rates, over 74% reductions in RDQ scores and marked decreases in symptom duration, with an acceptable safety and tolerability profile during the course of the study.
Metrics
References
Leiman DA, Riff BP, Morgan S, Metz DC, Falk GW, French B, et al. Alginate therapy is effective treatment for GERD symptoms: a systematic review and meta-analysis. Dis Esophag. 2017;30(5):1-9. DOI: https://doi.org/10.1093/dote/dow020
Chen JW, Vela MF, Peterson KA, Carlson DA. AGA clinical practice update on the diagnosis and management of extraesophageal gastroesophageal reflux disease: expert review. Clin Gastroenterol Hepatol. 2023;21(6):1414-21.e3. DOI: https://doi.org/10.1016/j.cgh.2023.01.040
El‐Serag H, Becher A, Jones R. Systematic review: persistent reflux symptoms on proton pump inhibitor therapy in primary care and community studies. Aliment Pharmacol Ther. 2010 Sep 20;32(6):720-37. DOI: https://doi.org/10.1111/j.1365-2036.2010.04406.x
Dekel R, Morse C, Fass R. The role of proton pump inhibitors in gastro-oesophageal reflux disease. Drugs. 2004;64(3):277-95. DOI: https://doi.org/10.2165/00003495-200464030-00004
World Gastroenterology Organisation (WGO). WGO handbook on heartburn: a global perspective. World Digestive Health Day (WDHD). 2015 May 29. Available from: https://www.worldgastroenterology. org/guidelines/gastroesophageal-reflux-disease/gastroesophageal-reflux-disease-english. Accessed on 5 November 2025.
De Ruigh A, Roman S, Chen J, Pandolfino JE, Kahrilas PJ. Gaviscon double action liquid (antacid & alginate) is more effective than antacid in controlling post‐prandial oesophageal acid exposure in GERD patients: a double‐blind crossover study. Aliment Pharmacol Ther. 2014;40(5):531-7. DOI: https://doi.org/10.1111/apt.12857
Kwiatek MA, Roman S, Fareeduddin A, Pandolfino JE, Kahrilas PJ. An alginate-antacid formulation (Gaviscon double action liquid) can eliminate or displace the postprandial ‘acid pocket’ in symptomatic GERD patients. Aliment Pharmacol Ther. 2011;34(1):59-66. DOI: https://doi.org/10.1111/j.1365-2036.2011.04678.x
Mandel K, Daggy B, Brodie D, Jacoby H. Review article: alginate‐raft formulations in the treatment of heartburn and acid reflux. Aliment Pharmacol Ther. 2000;14(6):669-90. DOI: https://doi.org/10.1046/j.1365-2036.2000.00759.x
Bor S, Kalkan IH, Celebi A, Dincer D, Akyuz F, Dettmar P, et al., Alginates: from the ocean to gastroesophageal reflux disease treatment. Turk J Gastroenterol. 2019;30(2):109-36. DOI: https://doi.org/10.5152/tjg.2019.19677
Dettmar PW, Sykes J, Little SL, Bryan J. Rapid onset of effect of sodium alginate on gastro-oesophageal reflux compared with ranitidine and omeprazole, and relationship between symptoms and reflux episodes. Int J Clin Pract. 2006;60(3):275-83. DOI: https://doi.org/10.1111/j.1368-5031.2006.00800.x
Zhao C, Wang J, Gong M. Efficacy and safety of alginate formulations in patients with gastroesophageal reflux disease: a systematic review and meta-analysis of randomized controlled trials. Eur Rev Med Pharmacol Sci. 2020;24(22):11845-57.
Fixed Dose Combinations Approved By DCG (I) From January 2020 to June 2020. 2020. Available from: https://cdsco.gov.in/opencms/resources/ UploadCDSCOWeb/2018/UploadApprovalMarketingFDC/nFrom%2001.01.2020%20to%2021.05.2020.pdf. Accessed on 24 November 2023.
Shaw M, Dent J, Beebe T, Junghard O, Wiklund I, Lind T, et al. The reflux disease questionnaire: a measure for assessment of treatment response in clinical trials. Health Qual Life Outcomes. 2008;6(1):31. DOI: https://doi.org/10.1186/1477-7525-6-31
Chiu CT, Hsu CM, Wang CC, Chang JJ, Sung CM, Lin CJ, et al. Randomised clinical trial: sodium alginate oral suspension is non-inferior to omeprazole in the treatment of patients with non-erosive gastroesophageal disease. Aliment Pharmacol Ther. 2013;38(9):1054-64. DOI: https://doi.org/10.1111/apt.12482
Giannini EG, Zentilin P, Dulbecco P, Iiritano E, Bilardi C, Savarino E, et al. A comparison between sodium alginate and magaldrate anhydrous in the treatment of patients with gastroesophageal reflux symptoms. Dig Dis Sci. 2006;51(11):1904-9. DOI: https://doi.org/10.1007/s10620-006-9284-0
Lai IR, Wu MS, Lin JT. Prospective, randomized, and active controlled study of the efficacy of alginic acid and antacid in the treatment of patients with endoscopy-negative reflux disease. World J Gastroenterol. 2006;12(5):747-54. DOI: https://doi.org/10.3748/wjg.v12.i5.747
Savla HM, Naik IV, Gargote C, Shashidhar N, Nair S, Menon MD. Physicochemical properties of various alginate-based raft-forming antacid products: a comparative study. Int J Basic Clin Pharmacol. 2021;10(12):1330-41. DOI: https://doi.org/10.18203/2319-2003.ijbcp20214449
Strugala V, Bassin J, Swales VS, Lindow SW, Dettmar PW, Thomas ECM. Assessment of the safety and efficacy of a raft-forming alginate reflux suppressant (liquid gaviscon) for the treatment of heartburn during pregnancy. Obstet Gynecol. 2012;2012:1-6. DOI: https://doi.org/10.5402/2012/481870
Jayanthy T, Reddy VP. Efficacy of an alginate versus proton pump inhibitor in the symptomatic relief of gastroesophageal reflux symptoms in pregnant women. Int J Reprod Contracept Obstet Gynecol. 2023;12(6):1616-21. DOI: https://doi.org/10.18203/2320-1770.ijrcog20231524
Mathew AS, Shilpa H. Is adjunctive alginate therapy beneficial in the treatment of laryngopharyngeal reflux disease in a rural Indian population? A prospective randomized study. Indian J Otolaryngol Head Neck Surg. 2022;74(S2):2104-10. DOI: https://doi.org/10.1007/s12070-020-02005-6
Downloads
Published
How to Cite
Issue
Section
